Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Titan doesn't have preferred shares, so the 1M shares he'd get by exercising his options would be worth the same as 1M shares owned by a private investor (about 420k CAD at the moment)
Per SEDI, Perry Genova received 1M options on April 17, 2017. Also visible via Canadian Insider.
These guys better be working for peanuts with option grants this big...
The shorts were selling high today to cover low later. That's how they make money.
Titan management would be smart to drop news on the clinical site selections while short interest is high. This would cause a short squeeze and the price would go up. THEN do the next raise!
Jasminder Brar is scheduled to speak in Palo Alto again in early May:
http://www.ipcounselcafe.com/agenda-may-2017/
Doesn't their lens cleaner solution require a bag of saline?
Is the port they're using the Applied Medical GelPoint?
That blue trim appears to be tape where the plastic sterile drapes are affixed to SPORT.
Are you proposing that Ximedica is working on two different robots with almost the same form factor and design for two different companies? Seems unlikely.
Just an observation, but the cleared up version that I posted seems to clearly show a live patient. Why would a cadaver have a bag of plasma hanging in the OR. Or a bag of saline. Or a drape at the neck?
Nice find. Hope this version helps "clear things up":
https://static.wixstatic.com/media/ca139e_6224117cdf8f49a49ff6c86f6da2ab34~mv2_d_2256_1496_s_2.jpg/v1/fill/w_1419,h_650,al_c,q_85,usm_0.66_1.00_0.01/ca139e_6224117cdf8f49a49ff6c86f6da2ab34~mv2_d_2256_1496_s_2.webp
According to the abstracts booklet from the ARVO 2017 meeting, Nabil Simaan has a current, paid relationship with Titan:
http://www.arvo.org/webs/am2017/sectionpdf/MOI/Session%20516%20Advancements%20in%20OCT.pdf
Page 7
Not surprising. Titan was subleasing office space from Octagon Capital (same address and suite), which seems to have gone bankrupt last year.
It certainly looks like he was answering the question at the time the pic was snapped
I spy Jasminder Brar:
Amazing panel on the art and science of #IP at #IPforward pic.twitter.com/JplHNGWok0
— Laura Kendall (Guenther) (@LauraGforce) April 13, 2017
New base shelf prospectus on SEDAR. $80M raise over 25 months.
Why has no one mentioned that a new base shelf prospectus valued at $80M is on SEDAR?
After some further research, it looks like the conference at which Jasminder Brar is speaking is connected with the IPfolio management software that Titan uses internally for managing their patents. Each of the speakers works for a company that is using IPfolio, and it is mainly geared toward other IP professionals who work in that space. Brar will be speaking as part of a panel.
With the last two base shelf prospectuses, Titan sold the maximum offering and then issued a new base shelf prospectus when it was sold all the way through. So yes, I expect them to issue a new one before the next raise.
Titan will need to issue a new base shelf prospectus before they do another raise since the last prospectus has now been fully sold through.
My personal belief is that the strike price for the warrants included with the recent offering was chosen so that they'd be in the money as soon as Titan announces the clinical trial sites over the next few weeks....almost like a built in raise within a raise.
Today's price action has me wondering if folks working at the three sites already know that they've been selected and and if the public announcement is impending. Just conjecture on my part, but it makes sense given the timeline McNally presented in his telecon remarks.
Randall bought those shares a few weeks ago. Not sure why that news story got recycled again today.
Not possible since the Titan Board adopted the shareholder rights (aka poison pill) plan back in 2015:
http://www.titanmedicalinc.com/titan-medical-inc-adopts-shareholders-rights-plan/
Basically if someone tries to buy a majority stake in the company without going through the proper channels, the terms of the agreement trigger to dilute the aggressor.
Titan's short interest decreased dramatically at the end of March. Total short interest contracted from over 9M shares to just a few thousand.
See:
http://www.theglobeandmail.com/globe-investor/investment-ideas/eye-on-shorts-what-bearish-investors-are-betting-against/article34651195/
I think an Intuitive buyout could probably happen at a small premium over the current PPS. Medtronic knows that Intuitive's weakness here is that their market cap will drop as soon as another robot comes on market from a big player (such as the Verb robot), so it's in Intuitive's best interest to sell before their monopoly is no more.
I thought I knew this company inside and out before today, but you guys just had me swallow the red pill. I'm going to have so much fun exploring PAIR now...
I'm going to be on this like a hawk from now on. Wow!
If you follow this history back a bit, there was a letter issued on March 14 indicating the patent would be granted shortly.
Thanks for the tip. This is possibly the best research ever posted to this board! The patent will be granted on April 25 according to this. That is huuuuuugggggeeee IMHO.
Where do you see this? I'm still showing it in the application phase.
This happens to be a really key patent...a grant here means the key tech for SPORT (the flexible instruments) is now legally protected.
I'm missing the clue here. What new patent grant? The last grant I see in the USPTO database is from August 2016, and the last application appeared in February of this year.
Medtronic was supposedly working on their own robot. If they're considering an acquisition of Intuitive, that means their robotics R&D program failed. The upshot for this company is that there would be one less competitor in the market.
Anyone want to weigh in on the rumor that is making the rounds regarding Medtronic possibly looking to pick up Intuitive Surgical in an M&A?
Microline may have requested anonymity because they also were the instrument supplier for Surgibot.
Yeah, this is definitely high risk, high reward. You have to invest what you can bear to lose if things don't end well for the opportunity to do well if they succeed.
Interesting thing about Advincula is that his haul from Intuitive has dramatically decreased over the past couple of years. He's not even in their top 10 anymore according to the Open Payments database.
On another note, Open Payments shows that Patel made a paid visit to Transenterix year before last, but is now on Titan's SAB. That speaks volumes IMHO
As of right now, Titan has no debt. Therefore, even if your retirement coach was correct, there'd be no debt to settle if Titan ran out of money and went out of business. They'd just sell their patents and the engineering behind SPORT and distribute the proceeds on a pro rata basis to the shareholders and then iHub would declare bankruptcy because this board would go dark.
Google for Boston Dynamics, a company Google bought awhile back. There are your Verb patents.
I don't understand your post. When I posted that there was new information on SEDAR, it was as an FYI to others on the board that there was new information to consume for due diligence, nothing more.
It's pretty well known here that I am not a believer in the Verb connection (I mean, there is even a line in the annual information statement that points out that they'd have to disclose such a relationship if it existed), so I wasn't trying to hand wave about some "connection". I am simply am interested in this technology and its potential to disrupt the current robotic space, and in the potential for Titan's technology to be acquired by a bigger player who is playing catch up with the other manufacturers that are coming to market with their own robots.
The only thing I'm really looking for right now is a sign that Titan has a full-up robot that has demonstrated its ability to perform surgeries for multiple indications from start to finish. My nirvana as an investor is the day that they PR that the robot was used to complete a surgery with the full up system software and final hardware in place. From that moment, this thing becomes immensely valuable as an MA target because they will no longer be talking about going to the moon. They'll have gone to the moon.
Nothing new in the new filings...
New filings up on SEDAR. Reading now....
Great find TOinvestor. That is *extremely* interesting!